Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia
2005-003449-15Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2007
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia comparing ISIS 301012 add-on with Placebo add-on (2 arms). Primary endpoint: Incremental LDL-C lowering at Week 28. Started Mar 2007; status: completed.
02
Drugs
mipomersen
03
Conditions
homozygous familial hypercholesterolemia (HoFH)hypercholesterolemia
Beyond the preview
Go deeper on 2005-003449-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003449-15.